摘要
背景:在过去的几十年中,大量的抗惊厥药物已被纳入治疗癫痫的药物集合中。然而,治疗中的两个主要困难仍未解决:耐药性癫痫的发展和药物对反应性患者的严重毒性反应的发生。对发现已知抗惊厥药物的策略的回顾性分析表明,对癫痫动物模型的筛选活动几乎是识别已上市化合物的唯一策略。然而,关于抗惊厥药物分子靶点的实际结构和功能信息以及对引起癫痫发作的分子改变的日益了解,可以更合理地识别活性化合物。目标:本综述汇编了用于发现新的抗惊厥候选药物的基于目标的策略,分为两个主要主题。第一个概述了计算方法(基于对接的虚拟筛选和分子动力学)以寻找与电压门控离子通道和酶碳酸酐酶相互作用的抗惊厥结构。第二个包括分析合成的活性化合物,通过抗惊厥药物的药效团组合同时作用于不同的分子靶标。 结论:目前对抗惊厥药靶点结构的了解使计算模拟成为发现和优化活性化合物的有吸引力的方法。将通过虚拟筛选不同靶标所获得的结果结合起来,可以产生多靶标化合物,作为合并已知药物支架的结构设计的替代方案。
关键词: 抗惊厥药物、癫痫、电压门控离子通道、碳酸酐酶、对接、虚拟筛选、多靶点药物、混合分子。
Current Medicinal Chemistry
Title:Computational and Synthetic Target-based Approaches to the Discovery of Novel Anticonvulsant Compounds
Volume: 28 Issue: 33
关键词: 抗惊厥药物、癫痫、电压门控离子通道、碳酸酐酶、对接、虚拟筛选、多靶点药物、混合分子。
摘要:
Background: During the past decades, an important number of anticonvulsant drugs have been incorporated into the collection of drugs to treat epilepsy. However, two main difficulties remain unsolved in therapy: the development of drug-resistant epilepsy and the occurrence of severe toxic effects caused by the medication in responsive patients. The retrospective analysis of the strategies for discovering known anticonvulsant drugs showed that screening campaigns on animal models of epilepsy have been almost the exclusive strategy for identifying the marketed compounds. However, the actual structural and functional information about the molecular targets of the anticonvulsant drugs and the increasing knowledge of the molecular alterations that generate epileptic seizures allow a more rational identification of active compounds.
Objective: This review compiles target-based strategies used for the discovery of new anticonvulsant candidates and is divided in two main topics. The first one provides an overview of the computational approaches (docking-based virtual screening and molecular dynamics) to find anticonvulsant structures that interact with the voltage-gated ion channels and the enzyme carbonic anhydrase. The second one includes the analysis of active compounds synthesized to act simultaneously on different molecular targets by the combination of pharmacophores of anticonvulsant drugs.
Conclusion: Current knowledge of the architectures of anticonvulsant targets makes computational simulations attractive methods for the discovery and optimization of active compounds. Combining the results achieved by virtual screening of different targets could lead to multitarget compounds, as an alternative to the design of structures that merge scaffolds of known drugs.
Export Options
About this article
Cite this article as:
Computational and Synthetic Target-based Approaches to the Discovery of Novel Anticonvulsant Compounds, Current Medicinal Chemistry 2021; 28 (33) . https://dx.doi.org/10.2174/0929867328666210506161234
DOI https://dx.doi.org/10.2174/0929867328666210506161234 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Strategies for Treatment of Inflammation-related Depression
Current Neuropharmacology Classical Neurotransmitters and Neuropeptides Involved in Major Depression in a Multi-neurotransmitter System: A Focus on Antidepressant Drugs
Current Medicinal Chemistry The Synthesis and Evaluation of Novel Lactate Dehydrogenase Nanobioconjugates
Current Nanoscience Immunogenicity, Immunopathogenicity, and Immunotolerance in One Graph
Anti-Cancer Agents in Medicinal Chemistry Sao Paulo Research Conference on Molecular Medicine and Pharmacogenetics, A Joint Meeting with the IUPHAR Sub-Committee on Pharmacogenetics and the Brazilian Pharmacogenetics Network, Sao Paulo, Brazil, September 18-20, 2008
Current Pharmacogenomics and Personalized Medicine Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Bioactive Compounds in Some Culinary Aromatic Herbs and Their Effects on Human Health
Mini-Reviews in Medicinal Chemistry Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Current Neuropharmacology Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Relationship Between Susceptibility to DMCM-Induced Generalized Motor Convulsions and Low-Affinity [3H]-Ouabain Binding in Membranes in Rat Brain
Current Molecular Pharmacology The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Antiepileptic Activity of Novel 2-(substituted benzylidene)-7-(4- fluorophenyl)-5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one Derivatives
Letters in Drug Design & Discovery Serotonin<sub>2c</sub> Receptor Constitutive Activity: In vivo Direct and Indirect Evidence and Functional Significance
Central Nervous System Agents in Medicinal Chemistry The Orexin System: A Potential Player in the Pathophysiology of Absence Epilepsy
Current Neuropharmacology Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Therapeutic Role of Zonisamide in Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Common Issues Among Asthma, Epilepsy, and Schizophrenia: From Inflammation to Ca<sup>2+</sup>/cAMP Signalling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Drug Treatment of Epilepsy: From Serendipitous Discovery to Evolutionary Mechanisms
Current Medicinal Chemistry